Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 7Daunorubicin 5Azacitidine 5venetoclax 3Decitabine 3ivosidenib 2decitabine and cedazuridine drug combination 2cedazuridine 2Mitoxantrone 2Idarubicin 2Etoposide 2treosulfan 1tagraxofusp 1revumenib 1quizartinib 1olutasidenib 1glasdegib 1gilteritinib 1fludarabine 1etoposide phosphate 1enasidenib 1cc-486 1Midazolam 1Itraconazole 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Drug Therapy 1Cobicistat 1CPX-351 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Myeloid, Acute × fludarabine × Clear all
NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Astellas Pharma Inc

Phase 3 Completed
371 enrolled 36 charts 2 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡